Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Events
  5. Asco 2022 Weekend Story Roundup
Vantage Logo
June 06, 2022

Asco 2022 weekend story roundup

  • author
  • Amy Brown
  • Jacob Plieth
  • Jacob Plieth
  • Madeleine Armstrong
  • Madeleine Armstrong

Evaluate Vantage has been reporting from the Asco 2022 meeting and has covered the following stories so far:

 

June 5:

Enhertu asks, how low can you go?

Investors clutch at the Tigit straws

Carvykti casts a long shadow

Merus gets some competition

 

June 4:

Merck’s follow-on immuno-oncology plan hits a myositis problem

Abbvie goes back to basics with navitoclax

The Tropical wind blows cold for Trodelvy

 

June 3:

Roche bids for the CD20 bispecific prize

Daiichi’s third conjugate progresses in breast and lung

Conferences

Related Companies

AbbVie
Adicet Bio
Affimed
Arcellx
Arcus Biosciences
AstraZeneca
BeiGene
Daiichi Sankyo
Elevation Oncology
Gilead Sciences
Gracell Biotechnology
Merck & Co
Merus
PMV Pharmaceuticals
Roche

Related Topics

Oncology
Phase III
Trial Results
Download PDF

Share This Article

 
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Related Articles

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 27, 2022

Asco 2022 – great expectations for Adicet, Arcellx and PMV

Vantage logo
December 15, 2022

Ash 2022 roundup

Vantage logo
April 28, 2022

Asco 2022 – early focus settles on Adicet

Vantage logo
August 19, 2022

Esmo 2022 preview – front-line liver cancer showdown

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up